New blood tests could sharpen CMV monitoring in transplant patients
NCT ID NCT07286461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether measuring two new viral markers (CMV-RNA and TTV-DNA) in the blood can give a clearer picture of CMV infection in patients who have had a stem cell transplant and are taking the drug letermovir to prevent CMV. Researchers will track 290 adult transplant recipients to see if these markers predict when CMV reactivates or when anti-CMV treatment is needed. The goal is to improve monitoring and reduce unnecessary treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- letermovir prophylaxis
- What this could lead to
- If successful, this could lead to more accurate monitoring of CMV infection in transplant patients, potentially reducing unnecessary treatments and improving outcomes.
- What could go wrong
- This is an observational study, not a treatment trial. The markers being tested may not prove reliable enough to change current practice. Results are exploratory and need further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Heinrich-Heine-Universitaet Duesseldorf
Düsseldorf, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test could tailor CMV prevention after stem cell transplants
- New chemo cocktail aims to boost stem cell transplant success in leukemia
- New drug cocktail aims to boost stem cell transplant success in elderly leukemia patients
- New drug may offer safer CMV prevention for kidney transplant patients
- New hope for lung transplant patients: drug may block dangerous virus
- New blood test may help protect kids from post-transplant infection